Hims & Hers stock in focus before open after weak Q1 outlook and BTIG downgrade
New York, Feb 25, 2026, 07:12 EST — Premarket Hims & Hers Health shares were last down 0.5% at $15.46 in late trading on Tuesday, as investors headed into Wednesday’s session still digesting the telehealth firm’s cautious near-term outlook. BTIG analyst David Larsen downgraded the stock to “neutral” from “buy” on Tuesday, pointing to what he called disappointing results, a soft first-quarter setup and rising legal and regulatory uncertainty around weight-loss products. (StreetInsider.com) The pressure stems from guidance issued with results on Monday, when the company forecast first-quarter revenue of $600 million to $625 million, below analysts’ expectations, and said